Search Within

Michael Scordo

Formats
  1. Meeting Abstract (250)
  2. Journal Article (104)
  3. Research Letter (15)
  4. Correspondence (7)
  5. Editorial (5)
  6. Review (4)
  7. Book Section (1)
  8. Guidelines (1)
Groups
  1. Bone Marrow Transplant (387)
  2. CTCR Scholars (387)
  3. Center for Hematologic Malignancies (387)
  4. Department of Medicine (387)
  5. Hematologic Malignancies, Division of (387)
  6. Survivorship Research (338)

More Groups

People
  1. Gunjan Shah (298)
  2. Sergio Giralt (278)
  3. Miguel-Angel Perales (177)
  4. Sean Devlin (152)
  5. Heather Landau (141)
  6. Parastoo Dahi (140)

More People

Years
  1. 2025 (22)
  2. 2024 (72)
  3. 2023 (81)
  4. 2022 (49)
  5. 2021 (27)
  6. 2020 (53)

More Years

Publications
  1. Blood (123)
  2. Biology of Blood and Marrow Transplantation (56)
  3. Clinical Lymphoma, Myeloma and Leukemia (36)
  4. Bone Marrow Transplantation (26)
  5. Blood Advances (21)
  6. Transplantation and Cellular Therapy (15)

More Publications

Publishers
  1. American Society of Hematology (144)
  2. Elsevier Inc. (122)
  3. Nature Publishing Group (40)
  4. American Society of Clinical Oncology (14)
  5. Wiley Blackwell (9)
  6. Oxford University Press (7)

More Publishers

Results (387)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • How we treat mature B-cell neoplasms (indolent B-cell lymphomas)
    Review

    Lumish, M.; Falchi, L.; Imber, B. S.; Scordo, M.; von Keudell, G.; Joffe, E.
    Journal of Hematology & Oncology (2021)

    Fulltext@MSK | Save
  • Case study—methotrexate toxicity, treatment, and measurement
    Book Section

    Bhatt, V.; Scordo, M.; Carlow, D. C.
    In Ketha, H.; Garg, U. (Eds.) Toxicology Cases for the Clinical and Forensic Laboratory (2020)

    Fulltext@MSK | Save
  • Superiority of thiotepa-containing conditioning regimens in patients with primary diffuse large B-cell lymphoma (DLBCL) of the central nervous system (CNS) undergoing autologous hematopoietic cell transplantation (autoHCT)
    Meeting Abstract

    Wang, T.; Scordo, M.; Ahn, K. W.; Chen, S.; Kharfan-Dabaja, M. A.; Herrera, A. F.; Hamadani, M.; Sauter, C. S.
    Blood (2020)

    Fulltext@MSK | Save
  • VRd versus KRd safety profiles in newly diagnosed multiple myeloma patients using real-world evidence data from a single institution: VRd has high rates of chronic neuropathy, and KRd has low rates of cardiopulmonary or renal toxicities when using optimized IV fluid management coupled with baseline cardiac workup
    Meeting Abstract

    Tan, C.; Diamond, B.; Hultcrantz, M.; Korde, N.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Shah, U. A.; Lu, S. X.; Patel, D.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Results of a phase 1 open label dose escalation trial of AB-205 (allogeneic engineered endothelial cell therapy) in adults with lymphoma undergoing high-dose therapy and autologous hematopoietic cell transplantation (HDT-AHCT)
    Meeting Abstract

    Scordo, M.; Budde, L. E.; Abedi, M.; Mulroney, C.; Fakhri, B.; Pawarode, A.; Dholaria, B.; Kavalerchik, E.; Aggarwal, S. K.; Qazilbash, M. H.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • A pilot study evaluating lenalidomide and CC-486 in combination with radiotherapy for patients with plasmacytoma (LENAZART study)
    Meeting Abstract

    Shah, U. A.; Werner, K.; Tavitian, E.; Devlin, S.; Mailankody, S.; Korde, N.; Hultcrantz, M.; Tan, C.; Lu, S. X.; Smith, E. L.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy in newly diagnosed multiple myeloma: final results from a clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Diamond, B.; Salcedo, M.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Rabbit anti-thymocyte globulin exposure (rATG) in CD34+ selected hematopoietic cell transplantation and its impact on immune reconstitution and outcomes in children and adults
    Meeting Abstract

    Lakkaraja, M.; Scordo, M.; Mauguen, A.; Cho, C.; Devlin, S.; Avecilla, S. T.; Boulad, F.; Cancio, M. I.; Curran, K. J.; Jakubowski, A. A.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Clinical impact of bridging therapy prior to commercial chimeric antigen receptor (CAR) T-cell therapies for relapsed/refractory lymphomas
    Meeting Abstract

    Imber, B. S.; Perales, M. A.; Flynn, J.; Ruiz, J. D.; Devlin, S.; Alarcon Tomas, A.; Hajj, C.; Batlevi, C. L.; Dahi, P. B.; Lin, R. J.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in patients with multiple myeloma treated with continuous lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
    Blood (2020)

    Fulltext@MSK | Save